

ANTIPSORIATICS, TOPICAL PRIOR AUTHORIZATION FORM (form effective 1/5/2026)

Prior authorization guidelines for **Antipsoriatics, Topical** and **Quantity Limits/Daily Dose Limits** are available on Geisinger Health Plan's website at <https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger>.

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		Total pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:			NPI:	State license #:
LTC facility contact/phone:			Street address:	
Beneficiary name:			City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:	

CLINICAL INFORMATION

Drug requested:	Strength:	
Dose/directions:	Quantity:	Refills:
Diagnosis (<i>submit documentation</i>):	DX code (<i>required</i>):	

**Complete all sections that apply to the beneficiary and this request.
 Check all that apply and submit documentation for each item.**

INITIAL requests

1. For a TOPICAL AhR AGONIST (eg, Vtama):

- For the treatment of PSORIASIS**, tried and failed or cannot try (due to a contraindication or an intolerance) to BOTH of the following:
 - A 4-week trial of a topical corticosteroid
 - An 8-week trial of a non-steroidal topical drug (eg, topical calcineurin inhibitor, topical retinoid, topical vitamin D analog)
- For the treatment of ALL OTHER diagnoses**, list other treatments tried (including start/stop dates, dose, outcomes, etc.):

2. For a TOPICAL PDE4 INHIBITOR (eg, Zoryve):

- For the treatment of PSORIASIS:**
 - Tried and failed or cannot try (due to a contraindication or an intolerance) topical calcipotriene
- For the treatment of SEBORRHEIC DERMATITIS**, tried and failed or cannot try (due to a contraindication or an intolerance) at least ONE of the following:
 - A 4-week trial of a topical antifungal
 - A 4-week trial of a topical corticosteroid

A 4-week trial of a topical calcineurin inhibitor (eg, pimecrolimus, tacrolimus)

For the treatment of ALL OTHER diagnoses, list other treatments tried (including start/stop dates, dose, outcomes, etc.):

3. For all other NON-PREFERRED Antipsoriatics, Topical (eg, vitamin D derivatives):

Tried and failed or has a contraindication or an intolerance to the preferred Antipsoriatics, Topical (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.)

RENEWAL requests

1. For a TOPICAL PDE4 INHIBITOR (eg, Zoryve):

Has documented evidence of a positive clinical response

2. For a TOPICAL AhR AGONIST (eg, Vtama):

Has documented evidence of a positive clinical response

3. For all other NON-PREFERRED Antipsoriatics, Topical (eg, vitamin D derivatives):

Has documented evidence of a positive clinical response

Tried and failed or has a contraindication or an intolerance to the preferred Antipsoriatics, Topical (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.)

Please submit to PromptPA <https://ghp.promptpa.com>

OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.

Prescriber Signature:

Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.